• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RVMD

    Revolution Medicines Inc.

    Subscribe to $RVMD
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: revmed.com

    Recent Analyst Ratings for Revolution Medicines Inc.

    DatePrice TargetRatingAnalyst
    7/16/2024$46.00 → $62.00Buy
    Needham
    7/12/2024$52.00Overweight
    Barclays
    7/8/2024$63.00Buy
    Jefferies
    4/12/2024$36.00 → $46.00Buy
    Needham
    4/10/2024$36.00 → $48.00Outperform → Strong Buy
    Raymond James
    3/11/2024$43.00Overweight
    Piper Sandler
    1/5/2024$31.00 → $34.00Neutral → Buy
    BofA Securities
    1/4/2024$41.00Outperform
    Wedbush
    11/16/2023$30.00Outperform
    Raymond James
    2/28/2023$32.00 → $38.00Neutral → Overweight
    JP Morgan
    See more ratings

    Revolution Medicines Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      11/8/24 10:52:39 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 6:30:27 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/14/24 9:26:21 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/13/24 5:13:53 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/13/24 6:06:55 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/12/24 5:11:14 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/9/24 5:22:05 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      2/8/24 10:17:35 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Revolution Medicines Inc. (Amendment)

      SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

      1/26/24 11:49:38 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Revolution Medicines Inc.

      SC 13G - Revolution Medicines, Inc. (0001628171) (Subject)

      11/9/23 5:18:33 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Revolution Medicines Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Revolution Medicines Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      12/9/24 4:15:16 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously

      7/16/24 8:15:42 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on Revolution Medicines with a new price target

      Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00

      7/12/24 7:33:26 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Revolution Medicines with a new price target

      Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00

      7/8/24 8:13:53 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham reiterated coverage on Revolution Medicines with a new price target

      Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $46.00 from $36.00 previously

      4/12/24 7:55:51 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines upgraded by Raymond James with a new price target

      Raymond James upgraded Revolution Medicines from Outperform to Strong Buy and set a new price target of $48.00 from $36.00 previously

      4/10/24 8:48:25 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Revolution Medicines with a new price target

      Piper Sandler initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $43.00

      3/11/24 7:46:59 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revolution Medicines from Neutral to Buy and set a new price target of $34.00 from $31.00 previously

      1/5/24 7:35:41 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Revolution Medicines with a new price target

      Wedbush initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $41.00

      1/4/24 8:44:54 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Revolution Medicines with a new price target

      Raymond James initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $30.00

      11/16/23 7:40:05 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines upgraded by JP Morgan with a new price target

      JP Morgan upgraded Revolution Medicines from Neutral to Overweight and set a new price target of $38.00 from $32.00 previously

      2/28/23 6:31:23 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Revolution Medicines Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Clyburn Frank

      4/A - Revolution Medicines, Inc. (0001628171) (Issuer)

      4/28/25 6:27:35 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $79,008 worth of shares (2,041 units at $38.71), decreasing direct ownership by 3% to 57,723 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/24/25 4:55:57 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff sold $56,921 worth of shares (1,458 units at $39.04), decreasing direct ownership by 2% to 59,764 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:43:42 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Goldsmith Mark A sold $458,255 worth of shares (11,738 units at $39.04), decreasing direct ownership by 3% to 441,564 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:43:20 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Anders Jack sold $72,771 worth of shares (1,864 units at $39.04), decreasing direct ownership by 2% to 115,006 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:42:31 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Horn Margaret A sold $119,385 worth of shares (3,058 units at $39.04), decreasing direct ownership by 2% to 153,533 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:41:43 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Kelsey Stephen Michael sold $128,599 worth of shares (3,294 units at $39.04), decreasing direct ownership by 1% to 293,051 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:40:55 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Wang Xiaolin gifted 2,718 shares, decreasing direct ownership by 3% to 102,321 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/19/25 5:40:18 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Cislini Jeff was granted 22,000 shares, increasing direct ownership by 56% to 61,222 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/4/25 7:03:20 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Anders Jack was granted 20,400 shares, increasing direct ownership by 21% to 116,870 units (SEC Form 4)

      4 - Revolution Medicines, Inc. (0001628171) (Issuer)

      3/4/25 7:02:51 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Revolution Medicines Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Revolution Medicines to Participate in April 2025 Investor Conferences

      REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company's participation are as follows: Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET To listen to a live webcast of any of these events, or access archived webc

      3/31/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Participate in March 2025 Investor Conferences

      REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in three upcoming investor conferences. Details of the company's participation are as follows: TD Cowen 45th Annual Healthcare Conference Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET Barclays 27th Annual Global Healthcare Conference Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET 2025 Leerink Partners Global Healthcare Conference Fi

      2/24/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

      REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-an

      2/19/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

      REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET. To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be availabl

      1/29/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

      REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on t

      1/6/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

      REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-

      12/5/24 4:05:49 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Revolution Medicines Inc. SEC Filings

    See more

    Revolution Medicines Inc. Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 10-Q filed by Revolution Medicines Inc.

      10-Q - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:10:24 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      5/7/25 4:05:10 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Revolution Medicines Inc.

      DEFA14A - Revolution Medicines, Inc. (0001628171) (Filer)

      4/29/25 4:39:20 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Revolution Medicines Inc.

      DEF 14A - Revolution Medicines, Inc. (0001628171) (Filer)

      4/29/25 4:38:04 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Revolution Medicines Inc.

      144 - Revolution Medicines, Inc. (0001628171) (Subject)

      3/14/25 4:47:11 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Revolution Medicines Inc.

      144 - Revolution Medicines, Inc. (0001628171) (Subject)

      3/14/25 4:18:03 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Revolution Medicines Inc.

      144 - Revolution Medicines, Inc. (0001628171) (Subject)

      3/14/25 4:09:41 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Revolution Medicines Inc.

      S-8 - Revolution Medicines, Inc. (0001628171) (Filer)

      2/26/25 4:44:42 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Revolution Medicines Inc.

      10-K - Revolution Medicines, Inc. (0001628171) (Filer)

      2/26/25 4:10:31 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Revolution Medicines, Inc. (0001628171) (Filer)

      2/26/25 4:05:09 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

      Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ

      12/15/22 7:00:00 AM ET
      $GERN
      $MRNA
      $PFE
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

      REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019

      7/13/22 7:00:00 AM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Revolution Medicines Inc. Financials

    Live finance-specific insights

    See more
    • Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

      Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial

      5/7/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web

      4/30/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

      Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA

      2/26/25 4:02:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

      REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-an

      2/19/25 4:05:00 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

      Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation Company on track to provide update on lung cancer programs in the fourth quarter of 2024 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with R

      11/6/24 4:02:32 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

      REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Follow

      10/30/24 4:05:23 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

      REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The company recently provided updated data on the clinical safety, tolerability and antitumor activity in patients with pancreatic ductal adenocarcinoma (PDAC) from its ongoing RMC-6236 mon

      8/7/24 4:05:41 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

      REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live

      7/31/24 4:05:11 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

      REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. As data from the first-in-human clinical study of RMC-6236 continue to mature, the company is preparing to advance RMC-6236 into randomized, controlled, monotherapy pivotal trials. The first trial expected to

      5/8/24 4:02:54 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

      REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live we

      5/1/24 4:05:56 PM ET
      $RVMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care